Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 50
GLP-1 obesity prescriptions: the fill gap
A 2026 real-world study examines which patient factors predict whether a semaglutide or tirzepatide prescription is actually filled.
Tirzepatide vs carpal tunnel: a 2026 study
A 2026 cohort study found tirzepatide users had lower rates of carpal tunnel syndrome than users of other GLP-1 or anti-obesity drugs.
GLP-1 therapy and IBS: TriNetX findings
In 6,665 matched IBS patients, GLP-1 receptor agonist use was tied to lower coded rates of abdominal pain, bloating, and chronic diarrhoea.
GLP-1 drugs for back pain and knee OA
A 2026 review from UT Health and Johns Hopkins asks whether GLP-1 drugs belong in pain practice for patients with obesity, low back pain, or knee OA.
SELECT trial: semaglutide and dementia risk
A SELECT sub-analysis found semaglutide 2.4 mg slowed a blood-based dementia risk score in 2,970 adults over 65. What the finding shows, and what it does not.
Semaglutide nanoparticles: 2026 HIP study
A 2026 study loaded semaglutide into microfluidic lipid nanoparticles and found a 6-fold permeability gain in intestinal cell models.
Semax and selank with SNRIs and Adderall
No interaction study covers semax or selank alongside SNRIs and Adderall. Here is what the pharmacology shows about the overlapping monoamine and GABA systems.
Tirzepatide: 10-year CVD risk in SURMOUNT-1
Post-hoc SURMOUNT-1 analysis: tirzepatide 15 mg cut predicted 10-year CVD risk by 1.92 pp at 72 weeks, widening to a 5.15 pp gap over placebo at three years.
Melanotan I and uneven pigmentation
Melanotan I can darken skin and existing pigmented spots, but a striped tan has no proven single cause and does not replace sun protection.
Do BPC-157, TB-500 or KPV need cycling?
No human trial has studied cycling for BPC-157, TB-500 or KPV. Here is what the preclinical literature and regulatory record say about on-off protocols.
Peru obesity drugs: budget impact explained
A 2026 analysis of 76,819 Peruvians found that full obesity drug coverage could cost up to S/143 billion per year. Here is what the numbers mean.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.